Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study.
Bastiaan M PrivéSteffie M B PetersConstantijn H J MuselaersInge M van OortMarcel J R JanssenJ P Michiel SedelaarMark W KonijnenbergPatrik ZámecnikMaike J M UijenMelline G M SchilhamAnnemarie EekTom W J ScheenenJ Fred VerzijlbergenWinald R GerritsenNiven MehraLinda G W KerkmeijerRobert J SmeenkDiederik M SomfordJean-Paul A van BastenSandra HeskampJelle O BarentszMartin GotthardtJ Alfred WitjesJames NagarajahPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
177Lu-PSMA appeared to be a feasible and safe treatment modality in patients with low-volume mHSPC.